Search
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalThe ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years. … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Ethoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnEthoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.
Categories: combinations of sulfonamidesArazasetron
go.drugbank.com/drugs/DB19237InvestigationalArazasetron is currently under investigation in clinical trial NCT05258773 (Evaluation of the Presence of SENS-401 in the Perilymph).
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalOn March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawnXanthinol is a very potent water-soluble derivative of niacin that can be found in diet supplements. It is also known as xanthinol nicotinate. … [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineMargetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … The HER2 oncoprotein, the product of the human _ERBB2_/mouse _neu_ genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR).
Benzphetamine
go.drugbank.com/drugs/DB00865ApprovedIllicitIt is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: d-N-methyl-N-benzyl-β-phenylisopropylamine, (+)-N-benzyl-N,α-dimethylphenethylaminePentetreotide
go.drugbank.com/drugs/DB12602ApprovedWithdrawnPentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalThis indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.
Products: NUCALA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML